Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
111 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Smoking Addiction - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smoking Addiction - Pipeline Review, H2 2016, provides an overview of the Smoking Addiction (Central Nervous System) pipeline landscape. In smoking addiction, people experience an uncontrollable dependence on cigarettes, which on stopping will cause severe mental, emotional or physical reactions. People addicted to smoking develop tolerance to nicotine. Nicotine acts on acetylcholine receptors causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological functions of many brain systems. This causes structural and functional changes in the brains of smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body get disturbed, leading to a condition called withdrawal syndrome. The body usually takes time to function in the absence of nicotine. The effects of smoking withdrawal stem from the lack of nicotine that can be overcome by nicotine replacement therapies such as the use of nicotine patch or nicotine chewing gum. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smoking Addiction - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Smoking Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Smoking Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 6, 7, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Smoking Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Smoking Addiction (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Smoking Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Smoking Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Smoking Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Smoking Addiction (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Smoking Addiction (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Smoking Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Smoking Addiction Overview 9 Therapeutics Development 10 Pipeline Products for Smoking Addiction - Overview 10 Pipeline Products for Smoking Addiction - Comparative Analysis 11 Smoking Addiction - Therapeutics under Development by Companies 12 Smoking Addiction - Therapeutics under Investigation by Universities/Institutes 14 Smoking Addiction - Pipeline Products Glance 15 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Smoking Addiction - Products under Development by Companies 18 Smoking Addiction - Products under Investigation by Universities/Institutes 19 Smoking Addiction - Companies Involved in Therapeutics Development 20 Aradigm Corp 20 Arena Pharmaceuticals Inc 21 Astraea Therapeutics LLC 22 Bioprojet SCR 23 CoMentis Inc 24 Embera NeuroTherapeutics Inc 25 Euthymics Bioscience Inc 26 Invion Ltd 27 Jeil Pharmaceutical Co Ltd 28 Johnson & Johnson 29 Lotus Pharmaceutical Co Ltd 30 Marinus Pharmaceuticals Inc 31 NAL Pharmaceuticals Ltd 32 Pfizer Inc 33 Selecta Biosciences Inc 34 Seoul Pharma Co Ltd 35 Zynerba Pharmaceuticals Inc 36 Smoking Addiction - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Combination Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 (metyrapone + oxazepam) - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 AKR-214 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 amitifadine - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Anatabine - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 AT-1001 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 BP-1.4979 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 ganaxolone - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 GTS-21 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 JLP-1603 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 JNJ-39393406 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 lorcaserin hydrochloride - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 nadolol - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 NFL-101 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 NIC-7DT - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 nicotine bitartrate - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 nicotine bitartrate - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 Nicotine Vaccine - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 PF-06413367 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 SEL-070 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 Small Molecule to Antagonize Cannabinoid Receptor for Smoking Addiction - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 Small Molecule to Inhibit Sodium Dependent Dopamine, Noradrenaline and Serotonin Transporters for Appetite Suppression and Smoking Cessation - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 Small Molecules to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 Small Molecules to Antagonize CHRNA3 and CHRNB4 for Smoking Cessation - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 SPO-1105 - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 URB-694 - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 Smoking Addiction - Dormant Projects 95 Smoking Addiction - Discontinued Products 97 Smoking Addiction - Product Development Milestones 98 Featured News & Press Releases 98 Nov 17, 2015: Invion Phase 2 Smoking Cessation Data: Results of Ongoing Analysis 98 Oct 05, 2015: Invion Successfully Completes Phase 2 Study of INV102 to Aid Smoking Cessation 99 Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation 100 Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation 101 Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation 102 Nov 04, 2014: Lorcaserin Meets Primary Endpoint And Confirms Proof-Of-Concept As Potential Aid For Smoking Cessation In Investigational Phase II Clinical Study 103 Nov 03, 2014: Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation 103 Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform 104 May 09, 2014: Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ (lorcaserin HCl) CIV by 50% 105 Jan 29, 2014: FDA clears path for "Smoking Cessation" clinical trial of INV102 (nadolol) 105 Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial 106 Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 106 Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs 107 Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint 108 Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation 108 Appendix 110 Methodology 110 Coverage 110 Secondary Research 110 Primary Research 110 Expert Panel Validation 110 Contact Us 110 Disclaimer 111
List of Tables
Number of Products under Development for Smoking Addiction, H2 2016 10 Number of Products under Development for Smoking Addiction - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 15 Comparative Analysis by Early Stage Development, H2 2016 16 Comparative Analysis by Unknown Stage Development, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Investigation by Universities/Institutes, H2 2016 19 Smoking Addiction - Pipeline by Aradigm Corp, H2 2016 20 Smoking Addiction - Pipeline by Arena Pharmaceuticals Inc, H2 2016 21 Smoking Addiction - Pipeline by Astraea Therapeutics LLC, H2 2016 22 Smoking Addiction - Pipeline by Bioprojet SCR, H2 2016 23 Smoking Addiction - Pipeline by CoMentis Inc, H2 2016 24 Smoking Addiction - Pipeline by Embera NeuroTherapeutics Inc, H2 2016 25 Smoking Addiction - Pipeline by Euthymics Bioscience Inc, H2 2016 26 Smoking Addiction - Pipeline by Invion Ltd, H2 2016 27 Smoking Addiction - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 28 Smoking Addiction - Pipeline by Johnson & Johnson, H2 2016 29 Smoking Addiction - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2016 30 Smoking Addiction - Pipeline by Marinus Pharmaceuticals Inc, H2 2016 31 Smoking Addiction - Pipeline by NAL Pharmaceuticals Ltd, H2 2016 32 Smoking Addiction - Pipeline by Pfizer Inc, H2 2016 33 Smoking Addiction - Pipeline by Selecta Biosciences Inc, H2 2016 34 Smoking Addiction - Pipeline by Seoul Pharma Co Ltd, H2 2016 35 Smoking Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2016 36 Assessment by Monotherapy Products, H2 2016 37 Assessment by Combination Products, H2 2016 38 Number of Products by Stage and Target, H2 2016 40 Number of Products by Stage and Mechanism of Action, H2 2016 42 Number of Products by Stage and Route of Administration, H2 2016 44 Number of Products by Stage and Molecule Type, H2 2016 46 Smoking Addiction - Dormant Projects, H2 2016 95 Smoking Addiction - Dormant Projects (Contd..1), H2 2016 96 Smoking Addiction - Discontinued Products, H2 2016 97
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
